Company intelligence / Profile preview

CRISPR QC

San Diego, California, USAcrisprqc.com ↗

Ownership: Private
Development stage: Commercial

Overview

The company has launched several products as part of its analytics platform that provide real-time data on key steps in the gene-editing workflow. These tools are designed to improve efficiency and accuracy in both therapeutic development and agricultural applications. No clinical results are reported as the company does not develop therapeutics itself but provides enabling technology.

Modalities: Gene editing (CRISPR/Cas systems)RNP complexes (Ribonucleoproteins)
Industry: Drug Discovery Services

Partnerships

Cardea Bio (exclusive license to the underlying CRISPR-Chip technology)National Institute of Standards and Technology/NIST relationship mentioned

Beyond the preview

Go deeper on CRISPR QC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CRISPR QC.

Explore the full profile